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Abstract
On example of Lactobacillus and Bifidobacterium strains, approaches in cre-
ation of human multistrain probiotic metabolite mixtures for different goals were 
proposed. Human probiotic lectin systems (LS) (mucosal, others) reveal func-
tions needed for organism. Advanced features of such systems include capability 
to recognize synthetic polymeric polyvalent glycoconjugates (GC)—imitators of 
natural ones (modified polysaccharides, glycoantigens of medical significance). 
Probiotic lectin systems function as imitators of multipro-/sym-/synbiotics in their 
resulting actions. They serve as carriers of the biotope glycoconjugate décor includ-
ing glycoprebiotics, glycometabiotics, glycodrugs, and agents supporting décor 
organization and resistance. Probiotic lectin systems represent new perspective 
system agents to improve the health of mucosal microbiocenoses (MB) organized 
as communicative bodies to be corrected according to the principle “there is body—
there are diseases.” They act as metabolomebiotics according to the principle “the 
network in the network.” They deepen biotope resistance allowing quicker return to 
balance. They support prophylactic and therapeutic procedures directed to prolong 
aging and improve quality of life. Multistrain metabolite constructions can predict 
perspective cellular formulas of multipro-/synbiotics for prophylaxis, supporting 
and accompanying therapy. Approaches developed are universal. They are useful in 
the study of any Gram-positive and eukaryotic (yeasts and yeast-like fungi) mono- 
and mixed cultures. The methodological principles proposed and described are of 
value for extended fields of clinical microbiology and medical bio-/nanotechnology.
Keywords: multistrain probiotics, probiotic lectins, glycoconjugates, 
microbiocenoses, antimicrobials
1. Introduction
Pro-/sym-/synbiotics are important objects of human microecology and medical 
biotechnology [1–4]. Microbes and human communicate each other by the way of 
recognition and binding glycoconjugates (GC) of varying pattern complexity by 
proteins (mainly adhesions and lectins) [5–9]. Lectin systems (LS) of symbiotic/
probiotic microorganisms (LSSM) recognizing GC represent new multifunctional 
factors [8–12]. LSSM are relatedly useful for human protein-/peptide-containing 
compounds and their complexes recognizing GC. LSSM reveal features of imitators 
of probiotics; members of new class of bacteriocin-like destructors of biofilms of 
yeast-like fungal and Gram-positive pathogens; systems cofunctioning together 
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with enzymes of all known classes; and agents possessing antipathogenic synergism 
of different LS in antimicrobial combinations (between LS of Lactobacillus species 
and Bifidobacterium species, between genera Lactobacillus and Bifidobacterium, 
between LS of probiotic bacteria and lectins from medical plants, between LSSM 
and antibiotics) (see Table 2) [8, 9, 13, 14].
LS reveal significantly higher multifunctionality (antimicrobial, cytokine-like, 
others) and adaptive ability in surroundings in comparison to any component of 
LS. Applied prospects of LSSM in microbial associations of biotopes in the human 
body are of promised interest. LSSM and their reactive GC support balanced func-
tioning in organism in respect to evolutionary created mucosal organ-like infra-
structures of mutual interest for human and biotope microbiocenoses (MB) [12].
The purpose of the review is to evaluate our approaches in creation of probiotic 
metabolite compositions influencing and improving health of human biotope 
microbiocenoses. The data presented will be of interest for investigators in the fields 
of both medical microbiology and laboratory and industrial medical biotechnology.
2. Methods
Lactobacillus and Bifidobacterium strains were from the collection of microor-
ganisms of the normal microflora of G. N. Gabrichevsky Institute for Epidemiology 
and Microbiology, and probiotics Bifidin and Acilact were products of our institute. 
Bacteria were grown in media containing casein hydrolysate and yeast autolysate. 
LSSM were extracted from the protein fractions 27–220 kD using isoelectrofocusing 
(IEF) in a plate of polyacrylamide gel (PAG) in a gradient of pH 4–8. Identification 
of proteins was performed by electroblotting on a hydrophobic membrane and 
staining with SYPRO blot stain (Bio-Rad Lab.). Nonstained proteins were evaluated 
by other spectrophotometric methods. The distribution of LSSM among proteins 
was determined by treatment of blots with biotinylated GC (GC-b) containing 
multiple residues of sugar(s) linked to the polyacrylamide (PA) linear core (like 
in external phenotypes of mucins and mucin-type glycans) (www.lectinity.com; 
1. α/β-D-GalNAc-PA-b (animal mucins, T antigens)*
2. β-D-GalNAc-PA-b (animal mucins)
3. β-D-GlcNAc-PA-b (insect chitins and chitosans)
4. β-D-Gal-PA-b (plant or animal galactans)
5. β-D-Gal-3-sulfate-PA-b (acidic animal galactans)
6. α-D-Man-PA-b (yeast mannans)
7. α-D-Man-6P-PA-b (yeast phosphomannans)
8. α-L-Fuc-PA-b (fucans from brown algae)
9. α-L-Rha-PA-b (Gram-negative rhamnans)
10. MDP-PA-b (bacterial peptodoglycans)
11. Adi-PA-b (A-blood group substance GalNAcβ1-3GalβА1-)
12. Fs-PA-b (Forssman antigen GalNAcβ1-3GalNAcβА1-)
13. Tαα-PA-b (bacterial antigen Galα1-3GalNAcα1-)
*In brackets—natural substances which are imitated
Table 1. 
A list of synthetic GC used.
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Table 1) followed by final treatment with streptavidin-peroxidase conjugate. The 
bound peroxidase on the blot was registered in the presence of a chemiluminescent 
substrate in regime of a real time in the system BioChemi System (UVP, CA). 
Antimicrobial activities and synergism of LSSM, antibiotics, and phytolectins were 
tested on solid agar media during the prolonged growth and survival of communi-
cative fungal bodies (CFB) in the presence of disks of antimicrobials. Biosurfactants 
were tested and calculated using detection of sample drop activity against mineral 
oil film on water surface (the appearance of transparent circles). Amino acid com-
positions of samples were established using standard amino acid analyzer column 
chromatography. Oxidoreductase systems were detected on blots after IEF-PAG, 
resulting in kinetic protein stain disappearance (decolorization). Hydrolase systems 
were visually evaluated on blots after IEF-PAG (resulting in hydrolysis, splitting, 
and partial asymmetrical disappearance of protein bands). Maillard reaction 
products were partially evaluated as browning in culture supernatant according to 
optical density at 420 nm.
3. Results and discussion
3.1 Symbiotic lectins as system regulators and delivery agents
LSSM function as metabolomebiotics regulating metabolome according to the 
principle “LSSM network—whole organism metabolome network or interactome” 
[15]. The network of LSSM is created in the following manner: lectin molecule of 
determined molecular weight (in the Laemmli system) is represented by LS includ-
ing forms of varying charge and possessing a range of biological and physiological 
activities; such a minimal LS can be further transformed in a natural manner 
into extended network of complexes and supramolecular ensembles as a result of 
directional and sequential cascade binding of carbohydrates and GC. As a result of 
forming complexes and ensembles, lectin specificity of complexes and ensembles 
can be modified or changed during further development of recognition cascade 
network that will change the summary vector of specificity of LS. The latter will 
result in dynamic qualitative and quantitative changes of the local biotope sur-
rounding. Thus, the final whole resulting network of LSSM (as metabolomebiotics) 
will regulate the whole metabolome and interactome of organism involving human 
glycome (carbohydrates and GC: glycoproteins, glycoenzymes, glycolipids, recep-
tors, and others [16]). The metabolome possesses the ability to back direct and 
reversible effects of LSSM representing a part of hierarchic interactome. Multiple 
forms of adapted functioning LSSM microbiocenosis in the biotope will depend on 
the originality developed in a joint process of evolution involving host body local 
infrastructures for the distribution and disposition of microbiocenoses (organ-type 
constructions of both host and microbiocenosis interests are possible) [11, 12]. 
LSSM are ready to realize biologically active GC (as prebiotics, therapeutic agents, 
and metabiotics) in such symbiotic organs. The network of LSSM functions as 
noncellular simulators of symbiotics (probiotics) in the direct or indirect (through 
human higher hierarchic protection systems) predictable manners. For example, of 
communications between LSSM and own human protection systems, LSSM (as well 
as phytohemagglutinins from plants of medical significance) and artificial poly-
meric GC influenced peritoneal macrophage mobility in a coupled manner depend-
ing on doses of agents; LSSM were involved in modulation of cytokine production 
by human blood leukocytes [9, 17].
New useful properties of LSSM can be predicted and verified (cofunction-
ing to enzymes, adhesion, etc.), based on the fact that LSSM form a functional 
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superfamily of symbiotic lectins (on example of probiotic lectins and lectins of 
nitrogen-fixing bacteria). In addition, LSSM are members of the new class of 
destructors of biofilms of yeast-like and Gram-positive pathogens that simplify 
antimicrobial choice of components among LSSM. Other possibilities to operate 
with LSSM include their potential participation in a set of hierarchic pathways of 
advanced human innate protective systems in biotopes for cross talks. Both types 
of communications allow LSSM to be a successful synergistic assistant against 
pathogens in biotopes together with other antimicrobials and antimicrobial physi-
cal stress factors. As a result, LSSM reveal prolonged (early and late) anti-Candida 
activities as cascade (coupled) actions possibly influencing microecological niches 
of pathogens within biotope [registered during coculturing in the first 3 days (early 
events; also involving probiotic-like leader strains of L. acidophilus and L. casei), 
1–2 weeks, or 2–3 months (late events)] [18].
The used GC are characterized with known chemical structures simplifying 
interpretation and prognostics of results. Such GC reveal potential of metabiotics 
which may use LSSM as carriers [8, 12, 19]. As highly homogenous, synthetic GC 
better functionally imitate natural GC targets [bacterial proteoglycans, fungal 
(phosphor)mannans, others] important for antimicrobial/anti-infectious actions of 
LSSM. As a result, LSSM are very perspective in delivery and deposition of adequate 
specific GC which are locally releasing as therapeutics possessing anti-infectious, 
prebiotic, and/or communicative signal abilities and actions.
In biotopes LSSM participate in continuous (on-duty) support and periodical 
(biorhythmic) completion and exchange of normal GC décor of cells, tissues, and 
organs that must provide delaying or stopping further the development of the spot/
island/mosaic-landscape-originated and directed/metastasized abnormal processes 
as well as conserve any negative currently developmental events (initiation of 
appearance and survival of tumor-like cells as a result of innate intercellular com-
munications involving lectin receptor-coupled cell surface receptor mosaics).
LSSM (natural combinative sets of LSSM-GC complexes) influence all yeast-like 
fungal phases of life by prolonging the degradation and lysis of pathogenic micro-
biocenosis massifs or biofilms in human biotopes (on examples of Candida species). 
In respect to CFB functioning as niches, lectins of lactobacilli (LL as preferentially 
mucins/mucus-recognizing) and lectins of bifidobacteria (BL as preferentially 
mannan-recognizing) synergistically act against internal and peripheral subniche 
territories, respectively. The late destructive and lytic events in CFB may also take 
place due to LSSM cooperative complex action as metabolomebiotics together with 
hydrolases involved in pathogen destruction network. Synergistic actions between 
LSSM and other antifungals increase resulting in final (early or late [also of apop-
totic origin]) antipathogenic events as shown in Table 2 [20].
Endogenous LS antimicrobial actions (e.g., intestinal probiotic bifidobacterial 
and lactobacillar LS against intestinal yeast-like fungi) provide more directed, 
sensitive, and completed resulting effectiveness against pathogens (the primary 
absence and further late complete destruction of residual resistant colonies in 
external and internal regions of CFB of Candida albicans) compared to the action 
of phytolectin mixture from grasses of medical significance in the same condi-
tions. In cases of antibiotic-resistant strains, relatively sensitive to LSSM C. albi-
cans strain 547 (less potentially pathogenic compared to the strain 515, see below), 
the sorbed lactobacillar cationic LS revealed their synergistic ability to “regener-
ate” original anti-Candida effectiveness of antibiotic (on example of nystatin) 
in the internal region of CFB of yeast-like fungus (appearance of pathogen-free 
landscape connected to the border of the disk antibiotic). The phenomenon of 
synergistic reparation of the original ability of the sorbed antibiotic indicates 
prospects of additional mechanisms of LSSM combinative actions and partially 
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describes how to increase resulting antifungal effectiveness during prolonged 
contact to pathogenic CFB at fungal late steps. In the case of more resistant (poten-
tially “more pathogenic”) fungal strains (like C. albicans strain 515), the sorbed 
Types of synergism Lectins* Distant positions 
(directions from left to
right)
CBF as targets, affinity, 
and significance
Between PL
Between identical PL disks aBL and 
aBL
p-aBL, c-aBL
(p-aBL—c-aBL)
C. albicans 991
Intra-genus
(Lactobacillus)
cLL and 
aLL
aLL and 
cLL
From p-cLL to CR
(p-cLL—p-aLL)
From p-aLL to CR
(p-aLL—p-cLL)
C. albicans 515, 547
C. albicans 515, 547
Intra-genus
(Bifidobacterium)
aLL and 
aBL
p-aLL and c-aBL
(p-aLL—c-aBL)
C. albicans strains
Intra-genus
(Bifidobacterium)
aBL and 
cBL
[PR aBL] and [CR aLL] C. albicans strains
Inter-genera
(Lactobacillus and 
Bifidobacterium)
aBL and 
aLL
aLL and 
aBL
[PR aBL] and [CR aLL]
(p-aBL—p-aLL)
[PR aLL] and [CR aBL]2
*
(p-aLL—p-aBL)
C. albicans strains
S. aureus strains
Between PL and phytolectins
Between PL and grass lectins 
(GL)
aLL and 
GL
cBL and 
GL
From aLL to CR
(p-MGBL—p-aLL)
From p-cBL to CR
(p-MGBL—p-cBL)
C. albicans 515
C. albicans 515
Between PL and antimycotics
Between PL and
amphotericin B
aBL p-Amphotericin B, c-aBL
(p-Amphotericin 
B—c-aBL)
C. albicans strains > C. 
tropicalis strains
Between PL and itraconazole aBL c-Itraconazole, p-aBL
(p-Itraconazole—p-aBL)
C. albicans strains
Between PL and
ketoconazole
aBL p-Ketoconazole, c-aBL
(p-Ketoconazole—c-aBL)
C. albicans strains
Between PL and
nystatin
cLL
cBL
From p-cLL to CR
(p-cLL—c-nystatin)
From cBL to CR
(p-cBL—c-Nystatin)
C. albicans 515, 547
C. albicans 515, 547
Between GL and
nystatin
GL From p-MGBL to CR
(p-MGBL—c-nystatin)
C. albicans 515
Multiple synergism
Between BL and LL aBL, 
aLL
In triangle of CFB 
landscape:
p-aBL + c-aBL + p-aLL
(p-aBL—c-aBL;
p-aLL—c-aBL)
C. albicans strains
(Not for C. tropicalis)
*Diffusion between disks placed on Sabouraud agar in Petri dishes (disk positions: p, peripheral; c, central; CR, 
central region, between p-disk and the center; PR, peripheral region, between p-disk and the border of agar). Disks 
included anionic (a) and cationic and (c) lactobacillar and bifidobacterial LSSM (aLL, cLL, aBL, cBL). MGBL as 
the mixture of the grass lectins from the mill of plants of medical significance: Potentilla album and Stellaria media. 
Lectins were used in subhemagglutinating doses (less 1 microgram/ml). Standard panel of disk antimycotics (HiMedia 
Lab. Pvt. Ltd.) was used. CFB, communicative fungal bodies.
Table 2. 
Antimicrobial synergism of LSSM and antibiotics.
Oral Health by Using Probiotic Products
6
bifidobacterial cationic LS synergistically increased anti-Candida action of the 
grass phytolectin mixture.
Results indicate that LSSM may also participate in temporary separation and 
conservation of natural infectious biofilms to prevent early visual landscape 
development of diseases. The latter may be perspective as the assistant factor of 
improving quality of life (its prolongation, mucus and skin reparations, cosmetic 
significance, etc.) as it can be expected using symbiotics [21].
On the whole, our experimental approach (observations of antagonistic rela-
tionships between LSSM and pathogens in prolonged stress conditions) and the 
data obtained are supported by the conception describing microecological stress 
events in organism as the normal but sensor natural reactions [22].
3.2 The choice of strains and their consortia possessing potential for constructing 
new multistrain pro- and symbiotics
Screening, choice, and selection of new or improved antimicrobial and other 
useful properties of symbiotic (probiotic) cultural properties of strains and con-
sortia of human MB are important and strategic goals in prophylaxis and therapy of 
diseases, increasing resistance of organism and the acceleration of patient rehabili-
tation [1–4, 23]. Among GC investigated, glycans of mucin type (mucosal glycans) 
reveal special interest [24].
On the basis of own results, we proposed new algorithm of screening adequate 
probiotic-like microorganisms and their consortia possessing increased directed 
anti-infectious LS to construct new multipro-/sym-/synbiotics. The algorithm using 
LSSM (involving complexes to GC) among a panel of key factors in creating multi-
probiotics (MP) included (a) the choice of synthetic GC-imitating bacterial proteo-
glycans and (phospho)mannans of yeast-like fungi; (b) identification of different 
LSSM (GC-type-dependent) among proteins of cultural fluids of probiotic strain 
or consortium of strains; (c) comparison of (GC-type)-dependent LS (evaluation 
of summary LS intensity, length of LS distribution in pH-gradient tested, mosaic 
asymmetric configuration of distributed forms in LS, major forms as dominating 
in contribution to antimicrobial actions of LS, minor forms as expressing signal 
regulators of biorecognition in microbiocenoses, signals of communications to 
surrounding infrastructures, as well as additional participants of recognition of 
new types of biomarker GC); (d) identification of unique sets of components of LS 
significant for typing strains, species, or genera; (e) revealing and choice of com-
binative sets of potential antimicrobial forms of LS for further control and testing; 
and (f) control of antimicrobial activities initiated, supported, and/or influenced 
by LS-containing preparations in other (nondependent) methods.
The data which were useful for constructing any multiprobiotics (Acilact-like) is 
presented in Table 3.
In Table 3 the data needed for constructing formulas of any MP are presented on 
example of strain component compositions of Acilact (the well-known MP which 
served as a model). Algorithm for constructing formulas includes a few steps:
The first step: For formulas of any MP of category A (formulas as sum of wishful 
selected superiorities): the choice of all parameters of superiorities of MP (No. 4 as 
MP in code notes: positions 1.3, 1.4, 1.6, 2.7, 2.8, 2.13, 2.14, 2.15, and 4.3; major ingre-
dient strain contributors are at the second position in the code sequences [from left 
to right] position in code).
The second step: For formulas of any MP of category B: accounting additional 
superiorities of MP [No. 4 as MP in code notes; selected minimal positions of 
parameters for No. 4 in sequence indicate maximal expression of the contrary 
(by implicity) parameters]. For example, in the case of No. 4 in codes 1.1 
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No. Parameters of supernatants, ranging MP and its strains, proposals (P) Code ranging MP 
and its strains*
1 Status of proteins
1.0 Content of partially hydrolyzed protein
K3III24 > MP > 100 ash > NK1
P: K3III24 as the main source of active or signal oligopeptides
3. 4. 2. 1.
1.1 Acidic proteins pI 4–5
NK1 > 100 ash > K3III24 > MP
P: NK1 as the main source of basis cytoagglutinating and adhesive agents 
coupled to a spectrum of biological activities
1. 2. 3. 4.
1.2 Cationic proteins pI 7–8
NK1 > K3III24 > 100 ash > MP
P: Strains and their combinations as sources of lectins and lectin-like agents 
coupled to exopolymeric substances of compounds
1. 3. 2. 4.
1.3 Oxidase-reductase systems pI 5–5.5
MP > 100 ash > K3III24 > NK1[absence]
P: NK1 without extracellular major oxidoreductase systems
4. 2. 3. 1.
1.4 Hydrolase systems
MP > K3III24 > 100 ash > NK1
P: NK1 without extracellular major hydrolases (caseinases, peptidases, 
others)
4. 3. 2. 1.
1.5 Level of aggregation upon storing concentrates
K3III24 > 100 ash > NK1 > MP[no aggregation]
P: Irreversibility for K3III24 (similar to red cell biofilm storing)
3. 2. 1. 4.
1.6 Ability in membrane ultrafiltration
MP > NK1 > 100 ash > K3III24
P: Technological advantage of MP as mixture of strains (mixture of strains 
is needed)
4. 1. 2. 3.
2 Status of amino acids
2.0 Production of amino acids
NK1 > K3III24 > MP > 100 ash
P: Low antagonism between certain strains within MP can be under 
consideration upon strain choice
1. 3. 4. 2.
2.1 Tyr (sites for serine proteinases, fluorophores)
K3III24 > 100 ash > MP > NK1
P: Tyr can serve as criterion of utilization of fluorophores
3. 2. 4. 1.
2.2 Phe (sites for serine proteinases, fluorophores)
NK1 > MP > K3III24 > 100 ash
P: Support of point 2, revealing mechanism for point 2
1. 4. 3. 2.
2.3 Fluorophores (Trp, Tyr) (excitation at 254 nm)
100 ash > K3III24 > NK1 > MP
P: Dominated contribution of Tyr and their derivatives
2. 3. 1. 4.
2.3.1 Fluorophores (excitation at 365 nm)
100 ash > K3III24 > NK1 > > MP
P: Degradation/ utilization in MP (fluorophores cannot be used as targets)
2 3 1 4
2.4 Gly (hydrophobic, anti-adhesion action)
NK1 > MP > K3III24 > 100 ash
P: Gly as natural additive to improve signal activities and communications
1. 4. 3. 2.
2.5 Leu (hydrophobic, site for peptidases)
(Parameter is slightly dependent on strain origin)
K3III24 > 100 ash > MP, NK1
3. 2. ¼**. 4/1.
2.6 Ile (hydrophobic, participation in synthesis of biologically active volatile 
fatty acids)
K3III24 > 100 ash > MP > NK1
3. 2. 4. 1.
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No. Parameters of supernatants, ranging MP and its strains, proposals (P) Code ranging MP 
and its strains*
2.7 Ala (partially from peptidoglycans, site for exopeptidases)
MP > K3III24, 100 ash > NK1
P: Antagonism between strains results in partial cell wall degradation in MP
4. 2/3. 3/2. 1.
2.8 Ser (sites for hydrolase splitting and O-glycosylation)
MP > K3III24 > 100 ash > NK1
P: Support of point 1.4
4. 3. 2. 1.
2.9 Thr (site for O-glycosylation)
NK1 > 100 ash > MP > K3III24
P: Thr as criterion for evaluation of metabolism of cluster square positions 
for recognition in proteins (in comparison to point 2.8)
1. 2. 4. 3.
2.10 Lys (from cationic poly/oligopeptides, site for serine
proteinases, participation in Maillard reaction)
MP > 100 ash > K3III24 > NK1
P: Support of point 1.4
4. 2. 3. 1.
2.11 Val (hydrophobic, participation in synthesis of biologically active volatile 
fatty acids)
K3III24 > 100 ash > NK1 > MP
P: Mostly important criterion concerning volatile fatty acids producing
3. 2. 1. 4.
2.12 Glu/Gln (also as sites for amidases)
NK1 > MP, K3III24 > 100 ash
1. 4. 3. 2.
2.13 Asp/Asn (sites for amidases and N-glycosylation)
MP, 100 ash > NK1 > K3III24
P: Partial support of point 1.4
4. 2. 1. 3.
2.14 His (participation in auto-oxidation of protein, high affinity to metal 
cations, activation of oxidases and heme)
MP > NK1 > 100 ash > K3III24
P: Potential for metal chelate affinity chromatography and immobilization 
(for microassays)
4. 1. 2. 3.
2.15 Arg (from cationic poly[oligo]peptides, destruction
during pigments forming in Maillard reaction)
MP > NK1 > K3III24 > 100 ash
P: One of the way of decolorization of MP
4. 1. 3. 2.
2.16 Met (antioxidant)
NK1 > MP > K3III24 > 100 ash
1. 4. 3. 2.
2.17 Cys2 disulfide bonds (oxidation of SH-groups into Cys2)
K3III24 > NK1 > MP > 100 ash[not observed]
3. 1. 4. 2.
2.18 Pro (Pro-bends in regular structures of proteins)
100 ash > MP > K3III24 > NK1[traces]
2. 4. 3. 1.
3 Status of biosurfactants
3.0 Associated biosurfactants in complexes >27 kD
NK1 > MP > > 100 ash > K3III24
P: NK1 as the main source of movable permeable (detergent like) complex 
effectors; support point 4.3
1. 4. 2. 3.
3.1 Biosurfactants active against mineral oil
K3III24 > MP > 100 ash > NK1
3. 4. 2. 1.
4 Other parameters
4.1 Emulsifiers
100 ash > NK1 > MP > > K3III24 [absence]
P: K3III24 needs combination to any other strain to increase cultural 
components (>27 kD) to be emulsified
2. 1. 4. 3.
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(maximal resulting hydrolytic activities in respect to acidic proteins; increased 
level of antimicrobial peptides), 1.2 (maximal resulting hydrolytic activities in 
respect to cationic proteins; increased level of antimicrobial peptides including 
bacteriocin-like), 1.5 (the minimal level of aggregation upon storing concen-
trates), 2.3 (the minimal level of fluorophores exciting at 254 nm; contribution 
of Tyr and Trp or their derivatives), 2.3.1 (the minimal level of fluorophores 
exciting at 365 nm; contribution of Trp); and 4.2 (the minimal level of colored 
products); the major ingredient strain contributors are accounted as the third 
position in code.
The third step: The final formulas (formulas of category C) include combinations 
of formulas A and B. Multifunctionality of parameters analyzed can be extended 
(as in cases of amino acids [25]).
Extended approach for constructing more adaptive mixtures of lactobacillar 
and bifidobacterial MP (on the basis of Acilact extended by accounting industrial 
bifidobacterial strains) is presented in Table 4.
As expected, taxonomically mixed probiotics (symbiotics) will possess 
increased survival in biotopes of human organism. The same principles and 
algorithm (as for formulas of Acilact variants described above) can be applied. 
Combinations of Acilact ingredient strains and ingredients of Bifidin (B. longum 
spp. adolescentis MS-42), Bioprotectin (B. bifidum No. 1), and other bifidobacterial 
probiotics produced in Russia are of priority interest (also due to the possibility of 
their usage as standard models).
Table 4 demonstrates algorithm of further passage from intra-genus cases 
(Lactobacillus) of Gram-positive MP to inter-genus cases of MP as combinations of 
probiotic lactobacilli and bifidobacteria of the human gut origin.
Selective sets of parameters (points in Table 4) indicate principle differences 
between lactobacilli and bifidobacteria (as blocks of lactobacillar and bifidobacte-
rial strains in 7-mark code). Completing lactobacillar/bifidobacterial synergism 
is expected and predicted. Selected combinations of strains from both blocks can 
be used for creation of directed MP. Other more complex cases include unblocked 
lactobacillar and bifidobacterial sequences within the code (additional prognostic 
conclusions are possible). Code positions “1” and “5” (both strains produce high 
levels of cytoagglutinating LS) reveal adjacent/similar behavior that indicates high 
level of compatibility of the strains NK1 and MS42.
No. Parameters of supernatants, ranging MP and its strains, proposals (P) Code ranging MP 
and its strains*
4.2 Pigment products [optical density at 420 nm]
K3III24 > NK1 > 100 ash > MP
P: K3III24 as the main potential source of neoglycoconjugates of 
nonenzymatical origin; MP as maximally decolorized product needed 
cofunctioning strain mixture; partial inverse correlation to point 1.3
3. 1. 2. 4.
4.3 Antimicrobial activity (toward a panel of diagnostic mainly Gram-negative 
bacteria)
MP > NK1 > 100 ash > K3III24
P: Support point 3; potential of K3III24 to other targets (against Gram-
positive bacteria and fungi)
4. 1. 2. 3.
*1, NK1 (Lactobacillus helveticus NK1); 2, 100 ash (L. helveticus 100 ash); 3, K3III24 (L. casei K3III24);  
4, multiprobiotic (MP) on example of variants of Acilact.
**Alternative positions.
Table 3. 
Strain code ranging for multiprobiotic construction on example of Acilact (the Lactobacillus multistrain 
probiotic).
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Further constructing other or extended multistrain symbiotics is depended on 
choice of important parameters of interest (to increase the number of comparable 
codes used in Tables 3 and 4). Important prospects in constructing taxonomically 
mixed symbiotic formulas are expected on the basis of identified LSSM sets of the 
strains as counted ingredients of multisymbiotic as well as evaluation of the rela-
tive contribution of LSSM types in resulting multifunctional activities of mixed 
product. For example, the general properties of LS of lactobacilli and bifidobacteria 
investigated by us are “recognition of mucin-type targets” more or less than “recog-
nition of mannan-type targets” for LL or BL, respectively [8]. As a result, LSSM-
dependent synergism (which can be directed and predicted using extended panel of 
GC for LSSM selection and choice) of new taxonomically mixed symbiotics can be 
achieved.
No. Parameters of concentrate (C), their ranging, proposals (P) Code 
ranging 
strains 
and MP
1 Antifreeze components >27 kD, pI 4–8
(against any type of crystal forming during IEF-PAG):
gall > bif1 > MS42 > NK1 > MP > K3III24, 100 аsh
P: bifidobacterial C for stabilization of K3III24 and 100 аsh
7. 6. 5. 1. 4. 
3/2*. 2/3.
2 Formation of organic crystals in the presence of components >27 kD
(in conditions of 7М urea, 5% saccharose, 8°С, night, IEF in slab of PAG):
рI 4–6: 3III24, 100 аsh > MP > NK1 > MS > bif1 > gall (not)
pI 6–8: K3III24, 100 аsh > MP > NK1 > gall>bif1 > MS42
P: Potential approach to micro- and nanoassembling effectors
2/3. 3/2. 4. 
1. 5. 6. 7.
2/3. 3/2. 4. 
1. 7. 6. 5.
3 Complex protein C > 27 kD:
pI 4–6: NK1 > MS42 > K3III24 > gall> 100 аsh > bif1 > MP
pI 6–8: NK1 > gall > K3III24 > MS42 > 100 аsh > MP > bif1
P: Donors of cationic bacteriocin-like associates with exopolymeric compounds
1. 5. 3. 7. 2. 
6. 4.
1. 7. 3. 5. 2. 
4. 6.
4 Adhesins as colorless transparent not water-soluble drops on
polystyrene (number of drops):
gall > MS42 > NK1 > bif1 > MP > K3III24 = 100 аsh(not)
P: The size and numbers of drops indicate level of emulsification of C compared to 
original supernatant
7. 5. 1. 6. 4. 
2/3. 3/2.
5 Associated biosurfactants:
bif1 > gall > K3III24 > MP > 100аsh > MS42 > NK1
P: C “NK1 + gall” and “NK1 + bif1” as synergistic antimicrobials
6. 7. 3. 4. 2. 
5. 1.
6 LSSM as mucin-binding:
pI 4–5.5: gall > MP > NK1 > MS42 > bif1 > K3III24, 100 аsh
pI 5.5–8: MS42 > bif1 > gall > NK1 > MP > 100 аsh, K3III24
P: C for delivery into intestinal and urogenital mucosal cavities
7. 4. 1. 5. 6. 
2/3. 3/2.
5. 6. 7. 1. 4. 
2/3. 3/2.
7 LSSM as mannan-binding:
pI 4–5.5: 100 аsh, K3III24 > NK1 > MS42 > gall > MP > bif1
pI 5.5–8: gall > bif1 > MS42 > NK1 > MP > 100 аsh, K3III24
P: Potential against eukaryotic (yeast and yeast-like), prokaryotic (staphylococci), 
and HIV/HIV-related infections; delivery into cell and cell organelles
2/3. 3/2. 1. 
5. 7. 4. 6.
7. 6. 5. 1. 4. 
2/3. 3/2.
1, NK1 (L. helveticus NK1); 2, 100 ash (L. helveticus 100 ash); 3, K3III24 (L. casei K3III24); 4, MP (Acilact); 
5, MS42 (B. adolescentis МS42); 6, bif1 (B. bifidum No. 1); 7, gall (B. gallinarum GB); C, concentrate 
(>27 kD) of cultural fluid supernatant; IEF, isoelectrofocusing; PAG, polyacrylamide gel; P, prognostic proposals; 
*Alternative position. Blocks of lactobacillar (boldface) and bifidobacterial (italic font) strains are shown.
Table 4. 
Strain code ranging for multiprobiotic construction on example of new multiprobiotics including bifidobacteria 
and lactobacilli.
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Universality of approach proposed in Table 4 means that the panel of com-
parative parameters of investigation is unlimited for selection. As advantages of 
this approach for creation of perspective formulas of multipro-/symbiotics, some 
properties of future combinative products can be predicted and verified.
Aforementioned codes (Tables 3 and 4) extend the potential of using tradi-
tional MP. Results open new possibilities for investigation of LSSM types among 
strains and constructed consortia to develop perspective GC-type-dependent LSSM 
combinations possessing needed actions toward human interactome. In terms of 
personalized medicine, individual LSSM applications are of reality. For example, 
LSSM could be applied as “a functional tissue biotope” or mucosal organ-specific 
agents and organizers of lectin-coupled reactions and activities [26, 27].
3.3 Anaerobic synergistic preparations containing LSSM for support of human 
protective systems
Due to high distribution in organism, oxidative stress (as the power destruc-
tive factor initiating diseases) needs the constant presence of the power protec-
tive antioxidant systems [28, 29]. Some therapeutic proteins regulating cellular 
consumption of oxygen can be involved into development of tumor and other 
side pathologies in organism. We isolated system anaerobic (without oxidases 
initiating of oxygen and peroxide radicals) preparations of acidic/anionic and 
alkaline/cationic LSSM from cultures of symbiotic (probiotic) industrial strains of 
human bifidobacteria and lactobacilli as consortia that were successfully applied. 
Such preparations devoid the ability to induce destructive oxidative stress (cross-
linking and inactivation of therapeutic proteins, etc.) in respect to surrounding 
infrastructures.
The used synthetic GC in our work were characterized with antioxidant prop-
erties in respect to LS as carriers of GC (prolongation of chemiluminescence of 
protective complexes was observed). Similar resulting protection of LSSM was also 
registered in the presence of neutral and cationic bifidobacterial and lactobacillar 
cultural exopolymeric compounds (EPC) of nonprotein origin (as observed on 
the blot after IEF-PAG). Acidic and alkaline anaerobic LS of bifidobacteria and 
lactobacilli revealed the following general antipathogenic actions: (a) own and 
overlapped/synergistic; (b) toward communicative bodies of microbial massifs 
and biofilms of the potentially pathogenic yeast-like fungi and Gram-positive 
bacteria. All four types of preparations of LSSM used were characterized by own 
mechanisms of antimicrobial actions in comparison to action of other antimicrobial 
systems (antibiotics, bacteriocins, phytolectins, subisotype products of isotypes 
С4В and С4А of the human complement component C4) [30, 31]. LS from human 
probiotic bacterial cultures revealed the ability to act as cascades in such reactions 
as initiation/changing or switching recognition of GC of different types (imita-
tors of mannans, mucins, components of bacterial walls, Forssman antigens, Tn, 
blood group substance A) using the same original pool of lectin forms of taken 
multistrain probiotic. The presence of cations Ru2+ (ingredient of SYPRO involved 
in photosensibilization) strongly increased discreteness and number of forms of 
acidic lectins—potential carriers and deliveries of GC. Stability of obtained mosaic 
asymmetric landscape pictures of the systems LSSM-GC as multistrain probiotic-
depending and multistrain probiotic-supporting biotope balance of recognition 
and reversible retaining/depositing of GC (therapeutics, biomarkers, others) was 
observed. Combinations of anaerobic LS-containing proteins revealed themselves 
in respect to yeast-like and Gram-positive pathogenic targets as more selective in 
the choice of the adequate regional territory of massif of pathogen and limitation of 
early and late time (depending on localization of targeted region of communicative 
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body of pathogen) for the mostly effective visible actions of LS, obtaining uniform 
pure landscapes of LSSM action on massif of Candida albicans (the absence or 
minimization of LSSM-resistant residual fungal colonies in the interacting intestine 
system “LS of human intestinal bifidobacteria and lactobacilli—human intestinal 
C. albicans”). Antimicrobial activities of LSSM and phytolectins (phytohemagglu-
tinin from the kidney bean) could be realized not only directly but also through the 
influence (together with synthetic mannans and mucins) in respect to macrophage 
migration as well as through inducing production of cytokines by stimulated blood 
lymphocytes (on the example of tumor necrosis factor-α). Results indicate pros-
pects of anaerobic LSSM as assistant ingredients of the possible drug forms.
3.4 Synbiotic minibioreactor using LSSM for screening GC
During the last time, synbiotics and symbiotics (as synergistic sum of probiotics 
and prebiotics) are of increased investigator interest due to their antimicrobial and 
other useful reactions [1, 2]. In this respect LSSM represent new class of antipatho-
genic proteins (possessing extended potential of application) which recognize dif-
ferent GC. LSSM represent multifunctional potential of relatively highly molecular 
mass polymeric metabolites of cultures of the human microbiota (microbiocenoses) 
and consortia (also multistrain probiotics) of human indigenous microorganisms. 
LSSM cofunction together with artificial and biologically active natural GC [32].
According to own results, we proposed suitable laboratory minisystem for 
screening prebiotic and therapeutical GP using LSSM and sterile heparinized insulin 
syringes of 1 ml volume. The following results were obtained: (1) LSSM-containing 
fraction stimulated production of both the whole and adhesive mass of bifidobacteria, 
(2) LiCl (15 mM and higher) increased dose depending on the number of adhesive 
colonies, (3) bifidobacterial LSSM (within pI 4–4.5) were characterized with strong 
affinity to anionic synthetic GC (possessing exposed residues of sulfated galactosides 
or, in a less extent of affinity, exposed residues of mannose-6-phosphates), and 
(4) sulfated glycosaminoglycans together with cations Li+ and LSSM as potential car-
riers of Li+ participated in functioning bioreactor imitating synbiotope (multiplication 
of bifidobacterial colonies and their survival were observed).
Proposed synbiotic system is perspective for screening prebiotic GC (as it is 
known for prebiotic derivatives of chitin, chitosan, fucoidan, and glycopeptides 
[33, 34]). Table 1 includes potential prebiotic sources such as chitin and α-L-fucan 
which react to LSSM (LSSM may serve carriers of metabiotic GC; the list of GC can 
be unlimitedly extended).
3.5 Membrane technological prospects of LSSM
Progress in membrane and solid-phased technologies using LS-GC interactions 
includes the potential of their application in microassays, biochips (membrane 
bound glycoarrays or lectin arrays), and biosensors [35, 36].
The use of affine pore hydrophobic (uncharged) membranes predictably 
covered with mosaics of multifunctional sets of LSSM (additional significant 
purification of LSSM on membranes is reached) allows prolonged storing LSSM 
without decreasing samples in activities. The following prospects of LSSM-GC 
combinations may be of practical interest: (a) antifungal covers of prolonged action 
in combination with antibiotics and physical factors of stress [radiation (ultra-
violet and ultrasonic), light (biorhythm “day-night”), temperature, pH, oxygen, 
season changes (also biorhythmic), others] and (b) chemiluminescent systems 
cofunctioning in regime of real time for medical and industrial biotechnology and 
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bionanotechnologies [our results include the following coupled systems: “low acidic 
LSSM, low acidic oxidoreductases of lactobacilli”; “alkaline bifidobacterial LS, alka-
line bifidobacterial exopolymeric compounds”; “neutral lactobacillar/bifidobacte-
rial LS, neutral lactobacillar/bifidobacterial biosurfactants”; “LS, strongly acidic  
(pI 3–4) serial phyto-oxidoreductases/phyto[glycosyl]oxidases”].
Membrane technologies using separated proteins, oligopeptides, and their com-
plexes (especially) together with intrinsic or exogenic (SYPRO dye) fluorescence 
registered in live bioimagination are especially sensitive and perspective (protein band 
discreteness using fluorescence technique was better compared to the chemilumi-
nescence technique). The latter allows identification stabile boundaries of the whole 
protein massifs for further establishment of LSSM and other biologically and physi-
ologically active components among protein mosaics. Bioluminescence (fluorescent 
technique in combination with chemiluminescence technique) in optimal (depending 
on the object and the goal of study) conditions allows express-ranging cultural fluid 
groups of proteins and LS according to molecular mass (for additional standardization 
and typing of strains), evaluation of interstrain synergism and contribution of protease 
and oxidoreductase systems of mono- and multistrain probiotics (symbiotics) and 
other type consortia, and identification of mosaics of complexes containing fluoro-
chromes in extended interval of pI/pH (complexes and cell wall fragments as carriers of 
visible energy which is ready for energetic exchange with surrounding infrastructures 
as well as for monitoring directed supramolecular assembling and their reorganization).
Aforementioned data presented develop other possible important prognostic 
approaches and proposals. The choice of wished prognostic (LSSM-selected-type 
and GC-type interactions)-directed events in biotope can be determined and 
regulated by involving GC types needed (panels of natural and artificial GC used in 
biotope; extending the list of GC indicated in Table 1 is possible). The use of artifi-
cial polymeric GC with established chemical structures allows receiving adequate, 
understandable, and reliable results.
According to the multifunctional potential of artificial GC used, resulting 
events in biotope can be the following ones: antipathogenic actions (the use of 
GC-imitating pathogenic cell surface structures), prebiotic and symbiotic (synbi-
otic) actions (the use of GC-imitating prebiotic structures), increasing own human 
organism protective systems (the use of GC-interacting and GC-regulating macro-
phages and macrophage-like lymphocytes through their systemic receptor lectins), 
antitumor actions (potential using antigenic GC together with LSSM as antagonists 
and synergists in intercellular antitumor and anti-infectious communications [37]), 
and cytokine lectin/lectin-like cascades initiated/regulated with LSSM potentially 
influencing redistribution of cytokine network in organism.
3.6 Prospects of LSSM for prophylaxis and therapy of infectious diseases
Innate immunity plays an important role especially when antibody immunity is 
under development, suppression, or alteration. So the search of new natural anti-
infectious agents is of actuality. In contrast to probiotic cells, LSSM (as systems of 
LL or LB) are not sensitive to the presence of antibiotics and chemotherapeutics as 
well as do not need special conditions for survival. LSSM function as metabolome-
biotics according to the principle “the network in the network”; participation of 
major lectins in supporting physiologically significant glycodecor of biotope muco-
sal probiotic compartments, and minor lectins—in signal communications; support 
of such compartments (compensation of the absence of probiotic cells in MB upon 
therapy with antibiotics, delivery of fucosylated and galactosylated prebiotics of 
mutual supporting influence between populations of bifidobacteria and lactobacilli, 
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cofunctioning to anti-infectious agents (antibiotics, metabiotics, GC) and cells of 
organism protective systems (macrophages and leukocytes).
We characterize LSSM (acidic, low acidic, cationic: aLL, laLL, cLL, aLB, and 
cLB) of domestic probiotics which recognize polymeric artificial GC mucin-like 
analogs of antigens and EPC (fungal and bacterial mannans, bifidobacterial α-L-
Fuc-containing, sulfated and phosphorylated).
Antimicrobial directions of LSSM action were established [26, 31, 38].
3.6.1 Anticandidosis activities
• Against intestinal and urogenital Candida of epidemiologically significant spe-
cies of group I (C. albicans and C. tropicalis: early action of aLB within the first 
2 days; delayed action of cLL and LB within 1–2 months; synergism between 
acidic and cationic LSSM, cLB, and grass lectins, aLSSM/cLSSM, and some 
antimycotics)
• Against Candida of epidemiologically significant species of group II (C. glabrata: 
inhibition of virulent factors such as fungal IgA1 and IgG proteinases, EC 3.4.21.72 
and EC 3.4.21., respectively [9])
• Against Candida of epidemiologically significant species of group III (C. krusei: 
delivery of potential effector GC on cell surface)
• Interruption of mycosymbiosis parasitism of Candida—Aspergillus: the drugs 
against candidosis as predictably affective against aspergillosis)
Activities of LSSM against staphylococci (on example of patients S. aureus 
isolates): aLL > aLB; aLL and aLB; LSSM activities accompanied with:
• Delayed degradation of microbial massifs
• Partial directed lysis of microbial massif
• Tearing away fragments of massif (by two mechanisms depending on lectin 
type)
• Synergism between aLL and LB in antistaphylococcal actions
LSSM possess potential of diagnostics and prognostics of biotope diseases [37]. 
Results support important principle approach that diseases of MB (as in the case of 
CBF according to the principle “there is the body—there are diseases”) reflect own 
“biotope diseases” in organism [39]. LSSM can be used in phenotyping prognostics 
and diagnostics of infectious processes in organism; for prophylaxis and therapy of 
candidoses, staphylococcoses, mixed fungal-bacterial infections, mixed symbiotic 
mycoses; innate infections; immunodeficiency and infections against the back-
ground of immunodeficiency, upon antibiotics-/chemo-/radiotherapy. Such GC 
effectors as metabiotics, prebiotics, glycoantigens, and drugs of selective directed 
action are of availability.
It is of importance to consider the participation of LSSM in supporting biotope 
mucosal MB in conditions of oxidative stress (cofunctioning of laLL and probiotic 
oxidoreductase systems) [26]. Panel combinations of LB and LL are perspective in 
early evaluation (before the inflammation) of status of MB of functionally different 
biotopes of the vaginal tract.
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LSSM are similar (in specificities, systemic action) to communicative lectins of 
intercellular reception in innate immunity.
LSSM act as essential part of human protective supersystem (the supersystem 
with probiotic type action) [31]. Such supersystems contract disturbing the balance 
of the body’s health processes; keep and maintain the integrity of biotope micro-
biocenoses like healthy consortia. There are supersystems with antimicrobial or 
antifungal action in organism.
3.7 Potential of results for innovations
Results obtained by us in a study of probiotics can be useful as a set of 
approaches in study of the following aspects of clinical microbiology and medical 
biotechnology (in brackets—significance and prospects of results for infectology) 
[40, 41].
3.7.1 Metabolite technologies
• Cultural metabolites 27–200 kD within pI 4–8 (separation of acidic and 
alkaline protein and nonprotein of taxonomically significant systems); phe-
notyping of strains in cationic region containing protected sets of proteins 
Subcytoagglutinating activities: initiatively coupled or non-coupled to lectin 
and cytoagglutinating activities (cytokine activities; synchronization of 
cultures for increasing vulnerability of pathogens; typing).
• Functional blotting analysis of cascade cultures in combinative nutrient 
media (NM) (as in the case of milk followed by transfer into “casein hydroly-
sate-yeast autolysate” media; monitoring lectins, enzymes, and exopolymeric 
compounds [EPC])
• Development of strain-supporting NM (comparison of blotted maps of 
components of cultures in identical conditions)
• The use of α-S-, β/γ-, and kappa-caseinases (increase of effectiveness of NM, 
accumulation of physiologically active protein and nonprotein metabolites and 
their complexes)
• Systems of proteinases, EPC depolymerases, and/or peroxidase-like catalases 
in cultures (revealing strain-dependent producers of enzymes, proteins, and 
EPC; evaluation of cytolysis populations, oxidative stress, virulent factors, 
changes, and aging of cultures upon passages and storage)
• Lectin systems: major and minor, building and signal, cross talk and quorum 
sensing (standardization of cultures and analysis of communicative networks) 
*Evaluation of early and prolonged landscape synergism of recognizing 
components of cultures and antibiotics (individual choice and replacement of 
combinations of probiotics and antibiotics upon therapy of patient)
• Natural and recombinant systems oriented to recognition of polyvalent glyco-
conjugate targets of known structure (standardization of strains; monitoring 
and revealing signals of carbohydrate metabolism)
• Imitation by cultural metabolites in respect to strain or consortium effective-
ness (standardization of strain multifunctionality)
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• The use of recognizing metabolites instead of cells or in combinations with 
cells for support of feeble living and antibiotic-sensitive cultures (also in cases 
of non-culturable microorganisms).
• Constructing balanced supporting MB of probiotic cell-metabolite consortia 
(constructing symbiotic consortia, balanced vaccines)
3.7.2 Intercellular and cell-metabolite technologies
• For Gram-positive bacteria (opportunistic and pathogenic)
• Sensor microbial systems of MB (revealing and using key antagonistic sys-
tems) Directed assembling of cytokine-cell gradients: reversible functional 
(1–2 days) or late irreversible conserved and partially inactivated (4–6 weeks), 
as in cases of biofilms containing erythrocytes—in microassay (evaluation of 
protection and degradation of human cells in the presence of pathogens)
• Biofilm forming as ranked quantitative and qualitative, early and delayed—in 
microassay (reactions of mono- and mixed biofilms)
• Species-dependent redistribution of antagonistic MB (prediction of mutual 
influence between species and strains of probiotics, opportunistic microbes, 
and antibiotics)
• Leader strains and species within MB (evaluation of temporary 
MB-destabilizing strains in coexistent antagonistic microbial populations)
• Destabilization and synchronization of MB by recognizing components of 
cultures for increasing future selective synergistic action of antimicrobi-
als and stress factors (increase of early and late suppression of pathogens) 
Microecological interniche early and delayed landscape relationships in cases 
of solid-phased and suspension microbial massifs, for microanalysis (evalua-
tion of opportunistic microbes and MB as communicative bodies opposed to 
mosaics of antimicrobials)
• Construction of active (involving probiotic leaders) and stabilizing (species-
dependent and resistant to antibiotics, probiotic-like supporting MB) consortia 
(using upon therapy)
• Strain-phenotyping dysbiotic MB using lectin systems (revealing early changes 
in patient MB in the presence of lectins of MB, for development of new strate-
gies of therapy)
• LS of probiotic consortia (directions of consortium formula actions can be pre-
dicted by constructing) as ingredients of functional food to support resistant 
functioning mucosal organs
4. Conclusion
The data presented consider aspects of constructing probiotic multistrain 
intra- and inter-genus Gram-positive bacterial metabolites on examples of 
bifidobacteria and lactobacilli of the human gut origin. Algorithms of creation 
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of 4- and 7-code MP formulas are presented and argued. It is of importance to 
consider LSSM and their GC as a new perspective protective basis/scaffold factor 
influencing and supporting human interactome, involving biotope infrastructures, 
signaling, and anti-infectious actions as well as cofunctioning together with other 
protective human systems [17, 42]. Results support the use of pro-/symbiotic LS 
as assistant-coordinated metabolomic agents; carriers for delivery and releasing 
GC, metabiotics (including simulators of cell surface patterns of opportunistic 
microorganisms), prebiotics, therapeutics, and antigens (for cofunctioning to 
antibodies); and reserves for decoration elements that support stabile function-
ing landscapes of the human cell surfaces and mucosal tissues. Probiotic lectins 
(interacting with synthetic GC simulators) are important for screening, typing, 
and selection of useful strains and their consortia supporting organs. The proposed 
LSSM-containing preparations promise LSSM using a soft adaptive multidirected 
network synergistically acting together with other protectors (also in conditions of 
the absence of oxygen [involving oxidative stress and forming of covalently bound 
by-products] within biotope). Variants of multipro-/sym-/synbiotics constructed 
can be perspective for prophylaxis for individuals and contingents as well as for 
supporting treatments of patients (before and postoperative period, during chemo-
therapy, etc.). Approaches developed are useful in study of interniche relationships 
of extended set of Gram-positive and fungal microorganisms in mono- and mixed 
cultures. Procedures can be applied in different fields of clinical microbiology and 
medical biotechnology.
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